LAST CHANCE TO GET IN BEFORE FDA APPROVAL .PRICE TARGET 2++ DOLLAR TOMORROW FOLKS ! GLTA
Market Cap : 28 M$ Cash: 3.7 M$ Price : 0,58 $
Shares Out : 45 M ( 23 M shares are held by Insiders + Institutions)
FDA Revises IntelGenx' CPI-300 PDUFA Date to November 10th
SAINT LAURENT, Quebec, Nov. 7, 2011 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX.V - News) (OTCBB:IGXT.OB - News) ("IntelGenx") today announced that the U.S. Food and Drug Administration ("FDA") has revised the CPI-300 Prescription Drug User Fee Act ("PDUFA") date to November 10th, 2011 from their previous guidance of November 13th, 2011. CPI-300 is a novel, high strength of Bupropion Hydrochloride (HCl), the active ingredient in Wellbutrin XL(R).